Key highlights
Explore more by category
Showing: 1 – 10 of 45 stories
27 October 2022 – 1 mins read
A word from CEO David Loew
“Our growth platforms have delivered strong sales performance, reflecting improving commercial execution and the strength for our portfolio.” CEO David Loew
14 October 2022 – 2 mins read
Ipsen becomes a founding sponsor of the second Biolabs innovation hub in Europe at Hopital Hotel Dieu, AP-HP
Ipsen announces that it becomes a founding sponsor of the second Biolabs innovation brain hub in Europe at Hopital Hotel Dieu, AP-HP, in Paris, France. The announcement builds on a 2018 commitment to a partnership with Biolabs for the development of a netw
11 October 2022 – 3 mins read
The Ixcellence Network®: celebrating 10 years of progress in improving the standard of care for patients living with debilitating neurological disorders
Continuing medical education is vital to maintaining the quality of clinical practice, which in turn can improve patient outcomes. As a pioneer in botulinum neurotoxin type A (BoNT-A) treatment, Ipsen has worked with a scientific steering committee of inte
05 September 2022 – 5 mins read
‘A Life in a Day’: the realities of living with FOP
I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans progressiva (FOP). FOP is a debilita
01 September 2022 – 2 mins read
Ipsen receives SBTi approval for climate targets
In October 2021, Ipsen pledged ambitious action on climate change. Today, we announce that Ipsen’s Climate Targets were approved by The Science Based Target initiative (SBTi). This approval confirms that our greenhouse gas (GHG) emission reduction target